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14 The Journal of Thoracic and Cardiobjective: This is the final report of a randomized controlled trial comparing the
erformance of CarboMedics (CarboMedics Inc., Austin, Tex) and St. Jude Medical
St. Jude Medical Inc, St Paul, Minn) bileaflet mechanical heart valve prostheses 10
ears after surgery.
ethods: Between 1992 and 1996, 485 patients undergoing mechanical heart valve
eplacement were randomized to receive CarboMedics (n  234) or St. Jude
edical (n  251) prostheses for aortic (n  288), mitral (n  160), or double (n
37) valve replacements. Patients were followed annually to the end of 2004.
esults: Demographic, preoperative, and operative characteristics were similar between
he 2 groups. The median follow-up was 10 years in both groups (CarboMedics 99%
omplete, St. Jude Medical 98% complete; 3879 patient-years of follow-up). Overall,
65 patients died, 25 of valve-related causes. Ten-year survivals were 66.4% (95%
onfidence interval: 59.6%-72.3%) and 64.7% (95% confidence interval: 58.0%-70.6%)
n the CarboMedics and St. Jude Medical groups, respectively (P .94). Freedom at 10
ears from valve-related mortality was 95.0% (95% confidence interval: 90.8%-97.3%)
n the CarboMedics group and 93.0% (95% confidence interval: 88.3%-95.9%) in the St.
ude Medical group. During follow-up, 34 patients had a thromboembolic event, 79
atients had at least 1 bleeding event, and 14 patients required reoperation. There were
o significant differences between the groups with respect to freedom from complica-
ions (P  .12); freedom from thromboembolism at 10 years (CarboMedics: 91.5%,
5% confidence interval: 86.5%-94.7%; St. Jude Medical: 92.2%, 95% confidence
nterval: 87.5%-95.2%); freedom from bleeding events (CarboMedics: 83.0%, 95%
onfidence interval: 76.6%-87.8%; St. Jude Medical: 77.5%, 95% confidence interval:
1.1%-82.7%); and freedom from death or valve-related complication (CarboMedics:
1.6%, 95% confidence interval: 44.7%-58.0%; St. Jude Medical: 46.2%, 95% confi-
ence interval: 39.7%-52.4%). Linearized rates per patient-year were 1.1% in the
arboMedics group and 0.8% in the St. Jude Medical group for thromboembolism;
.3% in the CarboMedics group and 3.2% in the St. Jude Medical group for bleeding
vents; and 0.72% in the CarboMedics group and 0.47% in the St. Jude Medical group
or nonstructural valve dysfunction. International normalized ratio values were similar
etween the 2 groups throughout the study period.
onclusion: At 10 years, the clinical outcome was similar with respect to these 2
echanical bileaflet prostheses.
vascular Surgery ● March 2007
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A
CDntroduced in 1977, the St. Jude Medical (SJM) (St. Jude
Medical Inc, St. Paul, Minn) mechanical bileaflet pros-
thesis was the first bileaflet pyrolytic carbon prosthesis.
he CarboMedics (CM) (CarboMedics Inc., Austin, Tex)
echanical bileaflet prosthesis was introduced as an inves-
igational prosthesis in 1986 and received Food and Drug
dministration approval in 1993. Both prostheses have
een widely used, and there are extensive observational
tudies describing their clinical performance.1-4 There are
ifferences in the design of the 2 prostheses,5 which could
onceivably confer differences in thromboembolic risk and
ther aspects of clinical performance. However, Akins6
oncluded that rates for valve-related complications were
ssentially comparable between CM and SJM valves, al-
hough data for the CM valve from a smaller study popu-
ation did show a slightly higher rate of thromboembolic
omplications in the mitral position, despite adequate anti-
oagulation. This finding has been supported by others.7,8 In
ontrast, Jamieson and colleagues7,9 found no significant
ifferences in thromboembolic tendency between the CM
nd SJM prostheses in isolated mitral valve replacement
MVR) or double valve replacement (DVR). A recent meta-
nalysis of these 2 prostheses found comparable thrombo-
mbolism and bleeding rates, but differing thrombosis rates
lower with the CM aortic valve and higher with the CM
itral valve compared with the corresponding SJM valves).
owever, whether the differences observed were of any
linical importance was doubtful.10 Long-term randomized
tudies to evaluate experiences with these prostheses have
een lacking to date, although an interim analysis of this
tudy at 5 years has been presented.11
Although some argue that randomized controlled trials
re not essential in evaluating prostheses, the conflicting and
ccasionally worrisome outcomes reported in observational
tudies make randomized controlled studies an important
ontribution to the assessment of the clinical performance of
articular valve prostheses.
This is the second and final report of a randomized
ontrolled trial comparing the clinical outcome of patients
ho received either CM or SJM standard mechanical heart
alves implanted at a single institution with a median
ollow-up of 10 years.
aterials and Methods
atient Recruitment
rom July 1992 to June 1996, patients scheduled to undergo
echanical heart valve replacement surgery at the Bristol Heart
nstitute under the care of a team of 5 consultant cardiac surgeons
ere recruited by individual consent into the study, which was
pproved by the local hospital research ethics committee. Exclu-
ion criteria included inability to obtain informed consent, known
ollow-up difficulties, surgery to the ascending aorta, history of
leeding diathesis, blood dyscrasias, major neurologic disorders a
The Journal of Thoraciceg, epilepsy), and long-term hemodialysis. Random assignment
as by card allocation at time of surgery.
urgery and Postoperative Management
ll operations were performed through a median sternotomy with
ardiopulmonary bypass and mild systemic hypothermia (28°C-
2°C). Myocardial protection consisted of intermittent antegrade 
etrograde cold (6°C) St. Thomas crystalloid or blood cardioplegia.
he prostheses used in both the CM and SJM groups were of
tandard design. Interrupted or continuous suturing technique was
sed at the discretion of the operating surgeon. All patients re-
eived postoperative subcutaneous heparin until the international
ormalized ratio (INR) was greater than 2 with warfarin adminis-
ration. On discharge, anticoagulation was managed in the com-
unity by general medical practitioners or at local hospitals ac-
ording to the British Society of Haematology guidelines.12 For
he initial part of the study, these guidelines recommended a target
NR of 3.0 to 4.5 for all patients with mechanical heart valves.
ubsequent revisions of this advice have acknowledged that mod-
rn bileaflet prostheses may be anticoagulated at a lower level.13
linical and Study Follow-up
atients were seen at 6 weeks for a clinical review and thereafter
eferred to their cardiologist for annual review. Study follow-up
as primarily by postal questionnaire sent to each patient on the
nniversary of his or her operation. Patients were contacted di-
ectly only when clarification of details was necessary. The family
ractitioner and/or hospital cardiologist was contacted, and hospi-
al health records were used where appropriate to clarify clinical
vents.
When a death occurred, the postmortem report was requested.
he death registry of the UK Office of National Statistics was used
o provide details of deaths that were otherwise unobtainable.
Adverse events, when reported, were categorized by a clinician
linded to valve type. Anticoagulation data (last 10 INR values)
nd drug dosages were obtained from the anticoagulant history
ooklet carried by the patient and filled out by the physician
esponsible for the patient’s care. Data collection was terminated at
he end of December 2004, the planned end of the study.
tatistical Analysis and Data Reporting
he original “Guidelines for Reporting Morbidity and Mortality
Abbreviations and Acronyms
AVR  aortic valve replacement
CM  CarboMedics
DVR  double valve replacement
INR  international normalized ratio
MVR mitral valve replacement
NYHA New York Heart Association
SJM  St. Jude Medical
SMR  standardized mortality ratiofter a Cardiac Valvular Operation”14 and its subsequent revi-
and Cardiovascular Surgery ● Volume 133, Number 3 615
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A
CDion15 were followed for definitions of valve-related complica-
ions, analysis, and presentation of data and results. The data were
ollected using a standard proforma and stored in a computerized
atabase. Continuous data are presented as a mean and standard
eviation or median and interquartile range as appropriate, and
ategoric data are presented as a number and percentage. Event-
ree survival was estimated using the Kaplan–Meier method and
ompared across CM and SJM groups using the Wilcoxon test.
ortality estimates, including linearized rates of percentage events
er patient-year, include in-hospital deaths. Age and gender stan-
ardized mortality ratios (SMRs) were calculated using UK Office
f National Statistics mortality rates for England and Wales in
001. Multiple logistic regression, adjusting for baseline New
ork Heart Association (NYHA), valve position, and follow-up
ear, was used to compare the proportion of patients in NYHA
unctional classes III/IV between the 2 study groups. Robust
tandard errors, clustered by patient, were used to take account of
he non-independence between annual NYHA assessments from
he same patient. Potential interactions were examined and re-
ained if significant at the 5% level. The results are presented as
dds ratios.
With respect to morbidity, significant bleeding events were
hose resulting in transfusion, hospitalization, or death, and throm-
oembolic events were any event, either transient or permanent,
here there was clinical corroboration. Multiple events during
ollow-up were included in the calculation of linearized rates for
hromboembolism and bleeding events. The composite end point
f valve-related complications included (1) thromboembolic
vents, (2) bleeding events, (3) reoperation, and (4) death due to
ny cause. INR values are displayed graphically. Standard errors
re adjusted to take account of the multiple INR readings per
atient per year. The data were analyzed using Stata version 8.2.
Stata Corp, College Station, Tex).
esults
atient Characteristics
uring the recruitment period a total of 590 patients under-
ent mechanical prosthetic valve replacement. Of these 590
atients, 485 (82%) consented and were randomized and
ollowed up (234 patients received a CM prosthetic valve,
nd 251 patients received an SJM prosthetic valve). Overall,
88 patients underwent aortic valve replacement (AVR),
60 patients underwent MVR, and 37 patients underwent
VR (Figure E1). The median ages were 63 years (inter-
uartile range 55-68) in the CM group and 63 years (inter-
uartile range 56-69) in the SJM group, and 45% of patients
ere female in both groups (Table E1). The majority of
atients were admitted on a planned elective basis, with 83
atients (17%) listed for urgent valve replacement and
8 patients (4%) listed for emergency valve replacement.
ore patients were in NYHA class III/IV among those who
nderwent MVR (66%) and DVR (70%) than in those
ndergoing isolated AVR (48%,), but the NYHA class
istribution was similar between the CM and SJM groups.
reoperative atrial fibrillation and anticoagulation therapy
ere also more prevalent among patients undergoing MVR f
16 The Journal of Thoracic and Cardiovascular Surgery ● Marcr DVR (55%) than in those undergoing AVR (9%),
nd again there was no difference between the SJM and CM
roups. The 2 groups were compared and found to be
imilar with respect to their baseline characteristics.11
Operative data describing suturing techniques, ischemic
ime, and cardiopulmonary bypass, as well as the cause of
alve dysfunction, have been presented.11 In patients un-
ergoing AVR the most common cause was calcific, com-
ared with a rheumatic cause in the MVR and DVR groups.
o differences between the CM and SJM groups with
espect to any operative variables or factors relating to
dditional procedures or the cause of valve dysfunction
ere found.
atient Survival
he early (30-day) mortality was 5.2% (n  25, CM 14,
JM 11, P  .43). A detailed description of the causes of
arly death is given in our 5-year interim report.11 The
edian follow-up was 10 years (interquartile range 9-11
ears) and was 99% and 98% complete for the CM and SJM
roups, respectively. During the total of 3879 patient-years
f follow-up (CM, 1897 patient-years; SJM, 1983 patient-
ears), there were 165 deaths (CM 81, SJM 84). The overall
urvival at 10 years was 66.4% in the CM group (95%
onfidence interval [CI] 59.6%-72.3%) and 64.7% in the
JM group (95% CI 58.0%-70.6%) (P  .94) (Figure 1, A).
he death rate was 4.3% per patient-year (95% CI 3.4%-
.3%) in the CM group and 4.2% per patient-year (95% CI
.4%-5.2%) in the SJM group. Postmortem diagnoses were
vailable in 36% of cases (CM 37%, SJM 35%). In cases
ithout a postmortem diagnosis, the cause of death was
ssigned by the clinical diagnosis. In 109 cases, death was
ue to cardiac causes, 25 of which were considered valve-
elated (CM 11, SJM 14). The specific causes of valve-
elated death are presented in Table 1. At 10 years, freedom
rom valve-related death was 95.0% in the CM group (95%
I 90.8%-97.3%) and 93.0% in the SJM group (95% CI
8.3%-95.9%) (P  .58).
SMRs were 1.99 (95% CI 1.55%-2.43%) in the CM
roup and 1.74 (95% CI 1.37%-2.11%) in the SJM group,
ndicating that the risk of death for study patients was higher
han for those of the same age and gender in the general
opulation. However, the SMRs for the CM and SJM
roups were similar (ratio of SMRs [CM/SJM] 1.15 [95%
I 0.83%-1.58%]).
Analysis by valve position showed that survival at 10
ears differed significantly among the 3 valve positions
P  .005). Overall, survival was 72.1% after AVR, 54.4%
fter MVR, and 62.3% after DVR (see Figure 1 for a
reakdown by prosthesis). Within each subgroup, no statis-
ically significant difference between the 2 prostheses was
ound (P  .53) (Figure 1, B-D).
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A
CDnticoagulation
or the assessment of anticoagulation status, 28,518 INR
eadings were available in 425 patients. The cumulative
istribution of INR measurements, pooled over all patients
nd follow-up periods, by prosthesis and valve position is
hown in Figure E2. No differences between the groups
ere found; the mean INR was 3.13 (standard error 0.023)
n the CM group and 3.12 (standard error 0.025) in the SJM
roup. There were no obvious trends in anticoagulation
uring the 10 years of follow-up.
alve-related Events
Thromboembolic events. Thirty-six (CM 20, SJM 16)
hromboembolic events were reported during follow-up in
4 patients. Two patients in the CM group reported 2
vents. Overall, 18 events (CM 10, SJM 8) were classified
s transient, 5 events (CM 2, SJM 3) were classified as
ermanent without residual disability, and 13 events (CM 8,
JM 5) were classified as permanent with residual disabil-
ty. A thromboembolic event occurred in 13 patients who
nderwent AVR, 19 patients who underwent MVR, and 2
Figure 1. Kaplan–Meier plots: overall patient surviva
survival for AVR only (C) and MVR only (D). CM, CarboM
aortic valve replacement; MVR, mitral valve replacematients who underwent DVR. The thromboembolic event e
The Journal of Thoracicate was 1.1% per patient-year (95% CI 0.6%-1.6%) in the
M group and 0.8% per patient-year (95% CI 0.5%-1.3%)
n the SJM group. Within the subgroup undergoing MVR,
he thromboembolic event rate was 1.9% per patient-year
95% CI 1.0%-3.5%) in the CM group and 1.5% per patient-
ear (95% CI 0.7%-2.8%) in the SJM group.
At 10 years, 91.5% of patients (95% CI 86.5%-94.7%) in
he CM group and 92.2% of patients (95% CI 87.5%-
5.2%) in the SJM group were free of thromboembolism
P  .63, Figure 2). Thromboembolism-free survival after
0 years in relation to valve position was predictably higher
n the aortic position at 94.8% (95% CI 91.1%-97%) com-
ared with the mitral position at 85.5% (95% CI 77.7%-
0.7%) (P  .003) (Figure 2).
Bleeding events. A total of 107 (CM 44, SJM 63) bleed-
ng events were reported during follow-up in 79 patients
CM 32, SJM 47). Fifty-eight patients (CM 21, SJM 37)
eported 1 event, 16 patients (CM 10, SJM 6) reported 2
vents, 3 patients (CM 2, SJM 1) reported 3 events, and 2
atients (SJM group) reported 4 bleeding events. Overall,
9 events (CM 38, SJM 51) required hospital admission, 17
, freedom from valve-related death (B), and patient
s; SJM, St. Jude Medical; CI, confidence interval; AVR,l (A)
edic
ent.vents (CM 6, SJM 11) included a blood transfusion, and
and Cardiovascular Surgery ● Volume 133, Number 3 617
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6
A
CDevent proved fatal (SJM group). One or more bleeding
vents occurred in 46 patients who underwent AVR, 23
atients who underwent MVR, and 10 patients who under-
ent DVR. The linearized bleeding event rate was 2.3% per
atient-year (95% CI 1.7%-3.1%) in the CM group and
.2% per patient-year (95% CI 2.4%-4.1%) in the SJM
roup. At 10 years of follow-up, 83.0% of patients (95% CI
6.6%-87.8%) in the CM group and 77.5% of patients (95%
I 71.1%-82.7%) in the SJM group were free of bleeding
vents (P  .12) (Figure 3).
Valve dysfunction and other valve-related complica-
ions. No cases of structural valve dysfunction or valve
hrombosis were clinically detected. There were 8 cases
f prosthetic valve endocarditis (CM 2, SJM 6), of which
were after AVR, 3 were after MVR, and 1 was after
VR. Of these patients, 5 underwent reoperation, all of
hom survived. The linearized event rate was 0.11% per
atient-year (95% CI 0.02%-0.42%) in the CM group and
.30% per patient-year (95% CI 0.13%-0.67%) in the
JM group. Echocardiographic evidence of a parapros-
hetic leak was recorded in 10 patients (CM 6, SJM 4)
ith no differences observed in relation to prosthesis
ype or valve position. In 5 cases, reoperation was indi-
ated, and all 5 patients survived the reoperation. The
0-year event-free rates for nonstructural valve dysfunc-
ion were 92.5% (95% CI 87.0%-95.7%) (0.72% per
atient-year) and 95.8% (95% CI 92.0%-97.8%) (0.47%
er patient-year) for the CM and SJM groups, respec-
ABLE 1. Follow-up and mortality
ariable
All
CM SJM
atients (No.) 234 251
ollow-up (mo)
Median (IQR) 120 120
(108-132) (108-120)
Maximum 145 144
atient-y 1897 1983
ompletion of follow-up (%) 99 98
arly mortality (30 d, No.) 14 11
verall mortality (No.) 81 84
Cardiac deaths 55 54
Valve-related 11 14
Hemorrhage 2 1
Nonstructural dysfunction 2 1
Prosthetic valve infection 1 4
Thromboembolism 3 3
Sudden unexpected/unexplained 3 5
Non-valve causes 44 40
Other causes 26 30
VR, Aortic valve replacement; MVR, mitral valve replacement; DVR, doub
nc, Austin, Tex); SJM, St. Jude Medical (St. Jude Medical Inc, St Paul, Mively (P  .33). p
18 The Journal of Thoracic and Cardiovascular Surgery ● MarcValve-related complication-free survival. Overall, 248
atients had at least 1 complication (thromboembolic event,
leeding event, reoperation, or death from any cause) during
ollow-up. The complication-free survival at 10 years was
imilar for the 2 prostheses (P  .37). At 10 years, 51.6%
f patients in the CM group (95% CI 44.7%-58.0%) and
6.2% of patients in the SJM group (95% CI 39.7%-52.4%)
ere free from valve-related complications (Figure 4, A). In
ontrast, a difference with valve position was seen, with the
VR group having a significantly higher event-free survival
han the MVR and DVR groups (overall comparison, strat-
fied by prosthesis, P  .0006, P  .012 for pairwise
omparisons among AVR, MVR, and DVR groups) (Figure
, B). At 10 years the event-free survival in the AVR group
as 56.7% (95% CI 50.6%-64.2%) compared with 37.0%
95% CI 29.1%-44.9%) in the MVR group and 37.5% (95%
I 22.2%-52.8%) in the DVR group.
ew York Heart Association Functional Class
he improvement in symptoms after valve replacement is
learly shown by the changes observed in the NYHA class
ver the study period, as illustrated in Figure 5. Overall,
5.9% of patients were in functional class III/IV before their
peration. One year later, this had decreased to 11.9% of
atients in NYHA class III/IV, increasing to 19.8% at 3
ears and 20.4% at 10 years (Table E2).
There was evidence to suggest that proportionally fewer
AVR MVR DVR
M SJM CM SJM CM SJM
139 149 75 85 20 17
120 120 120 120 108 120
-132) (108-132) (108-132) (108-132) (107-132) (108-120)
144 144 145 144 144 144
157 1241 573 617 167 125
99 98 99 99 100 100
10 4 3 4 1 3
41 39 34 38 6 7
28 19 22 29 5 6
3 4 7 9 1 1
0 1 2 0 0 0
0 0 2 1 0 0
1 0 0 4 0 0
1 1 1 1 1 1
1 2 2 3 0 0
25 15 15 20 4 5
13 20 12 9 1 1
e replacement; IQR, interquartile range; CM, CarboMedics (CarboMedicsC
(108
1
le valvatients in the CM group were in NYHA class III/IV
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A
CDhroughout the 10-year follow-up period compared with the
JM group odds ratio ([CM/SJM]  0.69 [95% CI 0.48%-
.99%, P  .05]). The proportion of patients with poor
unctional status also differed by valve position (P  .006).
ignificantly fewer patients who underwent AVR were in
YHA class III/IV compared with the MVR and DVR
roups, which were similar (P  .72).
iscussion
n this prospective randomized comparison of the SJM and
M mechanical bileaflet prostheses at 10 years, there was
o difference in survival or any of the other commonly
bserved indices of morbidity after heart valve replacement
perations: bleeding, thromboembolism, and prosthetic
alve dysfunction.
The strengths of this study were that it was prospective
nd randomized and to our knowledge remains the only
andomized controlled trial of these 2 heart valves. Al-
hough our randomization was simplistic by today’s stan-
ards,16 careful scrutiny of our study groups revealed no
pparent differences with respect to any important vari-
Figure 2. Kaplan–Meier plots: freedom from thromboem
only (C), and by position of valve replacement (D). Abbbles. In addition, follow-up information was collected on a
The Journal of Thoracicn annual basis in a consistent manner by the same observ-
rs during the 12-year study period.
However, we must question to what extent our finding of
o difference in the clinical performance of these 2 pros-
heses can be considered a definitive conclusion and to what
xtent this outcome may have been predictable based on the
tudy size and duration. Akins17 calculated in h i s learned
iscussion of our interim report that to definitively rule
ut any difference in performance between these 2 pros-
heses, taking into account the published ranges of com-
lications, would require some 10,000 patient-years of
ollow-up with a study size of perhaps 1400 patients in
ach group. We therefore must consider this study an
mportant further contribution to the information already
vailable on the clinical performance of these heart
alves and accept that the power of the study means it
annot conclusively be considered to demonstrate equiv-
lent clinical performance.
In the study as a whole, we found that survival after AVR
72.1%) was better than after MVR (54.4%) or DVR
62.3%). These differences were more apparent when over-
sm for all study patients (A), for AVR only (B), for MVR
ation definitions as in Figure 1.boli
revill survival and valve-related complications were consid-
and Cardiovascular Surgery ● Volume 133, Number 3 619
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A
CDred. For this combined end point, survival after AVR was
ignificantly higher than after both MVR and DVR (P 
012). This has been a common but not entirely consistent
nding in studies after mechanical valve replacement, and
Figure 3. Kaplan-Meier plots: bleeding event-free survi
(C), and by position of valve replacement (D). Abbrevia
Figure 4. Complication-free survival by study group
definitions as in Figure 1.
20 The Journal of Thoracic and Cardiovascular Surgery ● Marce know that late survival is as much a function of the risk
rofile of the starting population as a reflection of prosthetic
alve function. Nevertheless, the late survival and freedom
rom clinical events of patients after prosthetic MVR or
r all study patients (A), for AVR only (B), for MVR only
 definitions as in Figure 1.
nd position of valve replacement (B). Abbreviationval fo
tion(A) ah 2007
D
o
s
w
I
t
d
b
e
b
l
c
s
d
w
a
e
w
t
2
c
a
(
p
m
l
e
h
t
p
t
(
r
s
w
l
d
a
e
a
w
c
b
i
R
1
1
1
1
1
1
F
H
Bryan et al Surgery for Acquired Cardiovascular Disease
A
CDVR were disappointing and further support the application
f mitral valve repair whenever possible.
The only difference in outcome we identified was a
uggested difference in NYHA class during follow-up,
ith fewer patients in the CM group in NYHA class
II/IV. This difference did not seem to reflect preopera-
ive status, which was similar in the 2 groups. Echocar-
iographic analysis of left ventricular function may have
een helpful in clarifying whether there were any differ-
nces in left ventricular function between the 2 groups,
ut this was not part of the study.
The rates of thromboembolism and bleeding are at the
ower end of those recorded for these prostheses and
onsistent with previous observations.6 In particular, de-
pite the relatively small sample size there was no evi-
ence of an increased thromboembolic risk associated
ith the CM mitral valve. With reference to the antico-
gulation data, it is interesting that there was no differ-
nce in the management of these mechanical prostheses
ith respect to the position or type of prosthesis. Despite
his study being conducted during the 1990s and early
000s, with increasing understanding of prosthesis-spe-
ific anticoagulation, we found little evidence of any
daptation of the anticoagulation to the lower demands of
1) bileaflet prostheses and (2) prostheses in the aortic
osition. This may simply represent the rather crude
anagement of anticoagulation in the community.
To improve outcome for our patients, we must aim to
ower the levels of anticoagulation to reduce bleeding
vents without increasing the thromboembolic rate, which
as been shown to be effective.18 In addition, early institu-
ion of INR self-management can allow close control of
rosthesis-specific anticoagulation and consequently low
hromboembolic (0.21%/patient-year) and bleeding rates
igure 5. NYHA class by year of follow-up. NYHA, New York
eart Association.0.56%/patient-year).19
The Journal of ThoracicIt is at this point customary to suggest further possible
esearch to elucidate further the problem under study. A
tudy with more power would require a multicenter design
ith a large sample size. However, the increasing preva-
ence of mitral repair and the elderly surgical population
ictating implantation of biological valves make this less
nd less likely. It is probably far more realistic to acknowl-
dge that increasing information from observational studies
nd this randomized study provide an extensive basis on
hich to base a reasoned hypothesis that there is little to
hoose with respect to clinical performance between these 2
ileaflet prostheses.
We thank our surgical colleagues for their expertise in implant-
ng the valves.
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iscussion
r von Segesser (Lausanne, Switzerland). I congratulate Dr Bryan
nd Prof Angelini’s group for this nice study that gives answers to
ome questions that have been around for many years, namely,
hether there is a difference between the 2 types of valves. This
rings me to the first question.
In the 1990s there have been at least a half a dozen design
terations between different CarboMedics and St. Jude valve designs.
an you specify the type of valve that was used in your study?
Dr Bryan. All of these valves were standard St. Jude Medical
nd CarboMedics prostheses.
Dr von Segesser. There seemed to be a slight difference with
egard to thromboembolism between CarboMedics and St. Jude
alves, not when you look at the single valve replacements but at
he double valve replacements. Can you comment on that?
Dr Bryan. None of these differences attained anything like
tatistical significance. The number of thromboembolic events in
he double valve group was very low, really, but even so, it didn’t
ttain statistical significance, and the confidence limits widely
verlapped.
Dr von Segesser. There appears to be, at least graphically, a
ifference with regard to bleeding between the St. Jude Medical
nd CarboMedics valves. After 10 years of follow-up you have
bout 77% bleeding-free survival for St. Jude Medical versus 83%
or CarboMedics. If we look at a simple test like Fisher’s exact, it
omes up to about a 0.7 1-sided P value. I do not claim that this is
ignificant, but did you explore this any further?
Dr Bryan. This is an unusual article for me, because actually
he other 2 authors are both statistical advisors. So it is the first
tudy I have been involved with 2 statistical advisors and not 1, c
22 The Journal of Thoracic and Cardiovascular Surgery ● Marcnd perhaps that is a reflection of the statistical nature of these kind
f analyses. I am told that there are no differences in relation to the
leeding events, and, again, I haven’t presented P values on the
lides because my advisors tell me that when the confidence limits
verlap widely, it is not necessary.
Dr von Segesser. I agree that testwise there may not appear to
e a difference, but graphically it seemed to be impressive. I
onder if you have an explanation why there was so much more
leeding in the St. Jude Medical group?
Dr Bryan. I think all I can say is although it might appear
ifferent, if it is not statistically significant, then we have to accept
hat it is not different.
Dr von Segesser. I would dare not to agree. Absence of proof
s no proof of absence.
I have a final question. Did you have any objective measure-
ent for valve performance between the 2 groups?
Dr Bryan. No, we did not. There were no echocardiographic
ata.
Dr K. Rasheed (Islamabad, Pakistan). Congratulations on this
mpressive article and the quality of the presentation.
Regarding such a low rate of thromboembolism both in patients
ith single valves and double valves, would you tell us what INR
ou were maintaining for single and double valve replacements?
hank you.
Dr Bryan. With reference to the thromboembolic rate, as we
ll know from observational studies, there is a wealth of informa-
ion in relation to these 2 valves, and the thromboembolic rate that
e have recorded fits perhaps toward the lower end of those
ecorded in the literature, but it certainly is not the lowest.
In terms of the anticoagulation, in our country, anticoagulation
s essentially community monitored; we cover a wide geographic
rea. So the guidelines that are instituted really are general guide-
ines that are decided by the British Society of Hematology. At the
tart of this study period, the guidelines for mechanical prosthetic
alves was that the INR should be maintained for all valve models
n all valve positions in a range from 3 to 4.5. This was modified
n 1997 to indicate that for modern prostheses this should be
djusted. One of the reasons why I presented some of the antico-
gulation data, which we have a wealth, is that actually there is
ittle evidence of penetration of the concepts that have been
rought to our attention by people, such as Eric Butchart, that we
hould be anticoagulating in a prosthesis-specific manner, and
ertainly in our population there was no evidence of this.
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A
CDFigure E1. Flow chart showing
study recruitment and random-
ization. CM, CarboMedics;
SJM, St. Jude Medical.
ABLE E1. Baseline patient characteristics
ariable
All AVR MVR DVR
CM SJM CM SJM CM SJM CM SJM
atients (No.) 234 251 139 149 75 85 20 17
ge (y, median [IQR]) 63 63 63 64 63 63 63.5 61
(55-68) (56-69) (54-68) (55-69) (56-68) (58-69) (53-69.5) (49-68)
ale (%) 55 55 65 67 41 35 35 47
revious myocardial infarction (%) 12 10 10 11 17 9 5 6
revious heart surgery (%) 21 24 13 13 29 41 40 35
trial fibrillation (%) 31‡ 32† 7† 9* 65 65* 63* 59
istory of thromboembolism (%) 9* 13 5* 9 16 21 15 6
nticoagulation (%) 28* 28 9* 5 52 64 70 53
YHA functional class (%)
I 4 5 5 7 4 2 0 6
II 37 41 44 48 25 35 35 18
III 33 35 29 30 43 42 25 47
IV 25 18 22 16 28 20 40 29
oronary artery disease (%) 29 27 30 28 32 28 10 18
alve size
Aortic (median [IQR]) 23 (21-25) 23 (21-25) 21 (20-23) 21 (21-23)
19 mm (%) 16 9 25 19
21 mm (%) 21 33 35 44
23 mm (%) 63 58 40 37
Mitral (median [IQR]) 29 (29-31) 29 (29-31) 29 (27-31) 29 (29-31)
27 mm (%) 23 14 40 6
29 mm (%) 31 38 30 53
31 mm (%) 46 48 30 41
VR, Aortic valve replacement; MVR, mitral valve replacement; DVR, double valve replacement; CM, CarboMedics; SJM, St. Jude Medical; IQR,
nterquartile range; NYHA, New York Heart Association. One patient with DVR in the SJM group had a tricuspid valve (31 mm). *Missing data for 1 patient.
Missing data for 2 patients. ‡Missing data for 3 patients.
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A
CDFigure E2. Anticoagulation control.
INR, international normalized ratio;
SJM, St. Jude Medical; CM, Carbo-
Medics; AVR, aortic valve replace-
ment; MVR, mitral valve replacement;
DVR, double valve replacement.ABLE E2. New York Heart Association functional class: Baseline and annual follow-up to 10 years
ear
CarboMedics St. Jude Medical
I II III IV Total (100%) I II III IV Total (100%)
0 (preop) 10 (4%) 87 (37%) 78 (33%) 59 (25%) 234 13 (5%) 104 (41%) 88 (35%) 46 (18%) 251
1 120 (57%) 68 (32%) 20 (9%) 4 (2%) 212 116 (51%) 83 (37%) 18 (8%) 10 (4%) 227
2 115 (56%) 65 (32%) 19 (9%) 7 (3%) 206 101 (45%) 85 (38%) 23 (10%) 14 (6%) 223
3 96 (48%) 73 (36%) 20 (10%) 12 (6%) 201 78 (36%) 86 (40%) 36 (17%) 14 (7%) 214
4 94 (47%) 75 (38%) 17 (9%) 12 (6%) 198 82 (40%) 76 (37%) 30 (15%) 18 (9%) 206
5 80 (42%) 69 (36%) 30 (16%) 12 (6%) 191 81 (41%) 67 (34%) 33 (17%) 18 (9%) 199
6 81 (44%) 64 (35%) 26 (14%) 14 (8%) 185 76 (39%) 61 (32%) 38 (20%) 18 (9%) 193
7 76 (43%) 70 (39%) 24 (13%) 8 (4%) 178 82 (45%) 61 (33%) 21 (11%) 20 (11%) 184
8 71 (42%) 64 (38%) 21 (12%) 13 (8%) 169 76 (42%) 59 (32%) 27 (15%) 20 (11%) 182
9 55 (38%) 60 (42%) 16 (11%) 12 (8%) 143 66 (40%) 60 (36%) 20 (12%) 19 (12%) 165
0† 37 (38%) 43 (44%) 11 (11%) 6 (6%) 97 46 (46%) 30 (30%) 12 (12%) 11 (11%) 99
Not all percentages sum to exactly 100% because of rounding. †Follow-up ceased in December 2004, which meant that not all patients had the potential
o achieve 10-year follow-up.
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